TCGA-A2-A1FZ-01A-51R-A14D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 23
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.470
- PROTEIN_SECRETION+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- UV_RESPONSE_DN+0.360
- ADIPOGENESIS+0.330
- ESTROGEN_RESPONSE_EARLY+0.310
- KRAS_SIGNALING_UP+0.310
- ANGIOGENESIS+0.290
- APICAL_JUNCTION+0.290
- BILE_ACID_METABOLISM+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- MYC_TARGETS_V1-0.530
- E2F_TARGETS-0.490
- INTERFERON_ALPHA_RESPONSE-0.450
- G2M_CHECKPOINT-0.440
- SPERMATOGENESIS-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- MTORC1_SIGNALING-0.260
- OXIDATIVE_PHOSPHORYLATION-0.210
- DNA_REPAIR-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.862 |
| 2 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.856 |
| 3 | SRR5088898 | — | — | 0.853 |
| 4 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.853 |
| 5 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.852 |
| 6 | SRR6013580 | — | cohortA2 | 0.843 |
| 7 | SRR8518203 | — | A | 0.838 |
| 8 | SRR8613790 | — | A | 0.837 |
| 9 | SRR8613813 | — | D | 0.836 |
| 10 | TCGA-CQ-6227-01A-11R-1915-07 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |